Professional Media briefs: April 2012

Share this article:
Professional Media briefs: April 2012
Professional Media briefs: April 2012
Elsevier is launching the cross-disciplinary journal Fellowship of Postgraduate Medicine, Health Policy and Technology. Editor-in-Chief Wendy Currie's background includes academia, business consulting and the non-profit sector. The inaugural issue focuses on Electronic Health Records and will feature an interview with Sir Michael Rawlins, the chairman of NICE.

Monthly Prescribing Reference has released a Drugs & Bugs app that connects healthcare providers to the profiles of more than 100 antibiotics and almost 200 pathogens. The Apple- and Android- friendly app can also be used on the Kindle Fire and NOOK. It provides comparative charts by drug class and can be searched by pathogen, infection and drug names. Both MPR and MM&M are owned by Haymarket Media.

Journal EMBO Molecular Medicine is converting to an open-access model as part of Wiley-Blackwell's Wiley Open Access publishing program, Wiley and EBMO said. This is the second of EMBO's four journals to convert from a subscription-based model to open-access. Future articles will be published under the Creative Commons ­Attribution Non-Commercial License.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?